Rituxan Hycela (rituximab and hyaluronidase human) Subcutaneous
Defines EmblemHealth coverage, clinical criteria, dosing limits, renewal rules, billing codes, and limitations for Rituxan Hycela (subcutaneous rituximab+hyaluronidase) across Commercial, Medicaid, and Medicare members.
Maintenance therapy for Mantle Cell Lymphoma may be renewed until disease progression or intolerable toxicity.
Hairy Cell Leukemia may be renewed up to a maximum of 11 total doses.
Maintenance therapy may be renewed for up to a maximum of 2 years.
Updated initial criteria to add: Rituxan Hycela will not be used with intravenous chemotherapy agents or ibritumomab tiuxetan radioimmunotherapy; patient must be CD20 antigen expression positive.
Updated dosing limit chart and dosage details.
Added requirement that patient has received at least one full IV rituximab dose prior to initiating subcutaneous therapy for Medicare members (and included broadly in policy).
Preferred agents Ruxience and Truxima defined; Rituxan Hycela designated non-preferred for Commercial, Medicaid, and Medicare members (step therapy applies to new starts).
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.